Pediatric Gastroenterology, Hepatology & Nutrition

The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition (대한소아소화기영양학회)
권호 표지
DOI QR코드

DOI QR Code

Effects of Reactivation of Latent Epstein-Barr Virus Using Polymerase Chain Reaction on Acute Hepatitis A in Children

중합효소연쇄반응으로 확인된 엡스타인-바바이러스 재활성화가 소아 급성 A형 간염에 미치는 영향

  • Baek, Seung-Hyon (Department of Pediatrics, Yonsei University College of Medicine) ;
  • Kim, Sang-Yong (Severance Pediatric Liver Disease Research Group, Severance Children's Hospital) ;
  • Koh, Hong (Severance Pediatric Liver Disease Research Group, Severance Children's Hospital)
  • 백승현 (연세대학교 의과대학 소아과학교실) ;
  • 김상용 (세브란스 소아간질환 연구모임) ;
  • 고홍 (세브란스 소아간질환 연구모임)
  • Received : 2010.08.09
  • Accepted : 2010.08.28
  • Published : 2011.03.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: We previously reported that concurrent reactivation of latent Epstein-Barr virus (EBV) in children with hepatitis A virus (HAV) infection is common and EBV reactivation with HAV infection adversely affects the clinical features of hepatitis. However, the incidence of concurrent reactivation was not accurate because the detection of EBV reactivation was based on serologic methods. Therefore, we studied the effects of polymerase chain reaction (PCR)-proven EBV reactivation, thus a more precise concurrence, on acute HAV infection in children. Methods: PCR were conducted in 34 patients, who had enrolled previous study and diagnosed with acute HAV infection between January 2008 and June 2010. Their medical records were reviewed. Results: Among 34 patients with acute HAV infection, 12 patients (35.3%) had EBV reactivation which was proven using serologic and molecular biologic techniques. There were significant differences in the peak levels of AST and ALT between the reactivated and non-reactivated groups (p=0.001 and p<0.001, respectively). The duration of full recovery from hepatitis was more prolonged in the reactivated group (p<0.001). Clinical parameters, such as serum protein (p<0.001) and albumin concentrations (p<0.001), atypical lymphocyte count (p=0.001), prothrombin time-international normalized ratio (PT-INR, p<0.001), and splenomegaly (p<0.001), showed significant differences. The clinical features in the reactivated sub-group >10 years of age revealed more liver dysfunction compared to the non-reactivated sub-group. A comparison with a previous study was performed. Conclusion: PCR-proven reactivation of latent EBV in children with HAV infection is common and EBV reactivation with HAV infection adversely affects the clinical features of hepatitis, especially in older children.

목 적: 본 저자들은 급성 A형 간염 환아에서 EBV의 재활성화가 증가하였고 EBV의 재활성화가 A형 간염의 경과에 영향을 미치는 지 보고한 바 있으나 과거 연구의 한계를 극복하고자 중합효소연쇄반응을 시행하여 EBV의 재활성화가 확인된 급성 A형 간염 환아들의 임상경과를 분석하기로 하였다. 방 법: 과거 연구와 동일한 대상으로 2008년부터 2010년까지 세브란스병원에서 급성 A형 간염으로 진단받은 19세 이하의 환자 중 EBV PCR을 추가로 시행한 34명으로 제한하여 입원 당시의 나이, 성별, 간염으로부터 완전히 회복될 때까지 걸린 기간, 혈청검사 결과, 초음파검사 결과를 조사하였다. 대상 환아를 EBV의 비활성화군과 재활성화군으로 나누어 결과를 비교 하였고 10세를 기준으로 환아를 나누어 비활성화군과 재활성화군을 비교하였으며 이번 연구 결과와 과거연구 결과에서 유의하게 나온 항목을 비교분석하였다. 결 과: 재활성화된 비율은 35.3%였고 비활성화군과 재활성화군을 비교하였을 때 AST (p=0.001), ALT (p<0.001), AST/ALT ratio (p=0.002), 이환 기간 중의 최소 단백량(p<0.001), 이환 기간 중의 최소 알부민(p<0.001), 비정형림프구의 백분율(p=0.001), PT-INR (p<0.001), 간염회복기간(p<0.001), 비장비대(p<0.001)가 통계적으로 유의한 차이를 보였고 10세 미만에 비해 10세 이상의 환아에서 EBV가 재활성화 되었을 때 임상양상이 더 좋지 않았다. 지난 연구결과와 비교하였을 때 최소 혈청 단백농도(p<0.001)가 추가로 유의하였으며 10세 미만의 환아군에서 PT-INR의 차이가 사라지고 10세 이상의 환아군에서 최소 혈청 단백농도가 추가로 유의한 결과를 보였다. 결 론: 중합효소연쇄반응을 이용한 본 연구에서도 급성 A형 간염 환아에서 EBV의 재활성화가 흔하며 간염의 경과에 좋지 않은 영향을 미치고 나이가 많은 환아에서 더 좋지 않은 영향을 미치는 것으로 확인할 수 있었다.

Keywords

References

  1. El-Kamary SS, Cheng TL. Hepatitis A. Pediatrics in Review 2005;26:75-6. https://doi.org/10.1542/pir.26-2-75
  2. Jung YK, Kim JH. Epidemiology and clinical features of acute hepatitis A: from the domestic perspective. Korean J Hepatol 2009;15:438-45. https://doi.org/10.3350/kjhep.2009.15.4.438
  3. Hallee TJ, Evans AS, Niederman JC, Brooks CM, Voegtly H. Infectious mononucleosis at the United States Military Academy. A prospective study of a single class over four years. Yale J Biol Med 1974;47:182-95.
  4. Asano N, Yamamoto K, Tamaru J, Oyama T, Ishida F, Ohshima K, et al. Age-related Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disorders: comparison with EBV-positive classic Hodgkin lymphoma in elderly patients. Blood 2009;113:2629-36. https://doi.org/10.1182/blood-2008-06-164806
  5. Gotlieb-Stematsky T, Rannon L, Vonsover A, Varsano N. Stimulation of antibodies to Epstein-Barr virus (EBV) in acute viral infections. Arch Virol 1978;57:199-204. https://doi.org/10.1007/BF01315084
  6. Stowe RP, Pierson DL, Barrett AD. Elevated stress hormone levels relate to Epstein-Barr virus reactivation in astronauts. Psychosom Med 2001;63:891-5. https://doi.org/10.1097/00006842-200111000-00007
  7. Nystad TW, Myrmel H. Prevalence of primary versus reactivated Epstein-Barr virus infection in patients with VCA IgG-, VCA IgM- and EBNA-1-antibodies and suspected infectious mononucleosis. J Clin Virol 2007;38: 292-7. https://doi.org/10.1016/j.jcv.2007.01.006
  8. Besnard M, Faure C, Fromont-Hankard G, Ansart-Pirenne H, Peuchmaur M, Cezard JP, et al. Intestinal pseudoobstruction and acute pandysautonomia associated with Epstein-Barr virus infection. Am J Gastroenterol 2000;95: 280-4. https://doi.org/10.1111/j.1572-0241.2000.01709.x
  9. Drebber U, Kasper HU, Krupacz J, Haferkamp K, Kern MA, Steffen HM, et al. The role of Epstein-Barr virus in acute and chronic hepatitis. J Hepatol 2006;44:879-85. https://doi.org/10.1016/j.jhep.2006.02.006
  10. Lavin AC, Roman JG, Zarate SA, Porras MC, Caviedes JR. Acute upper gastrointestinal bleeding associated with Epstein-Barr virus reactivation in an immunocompetent patient. Am J Gastroenterol 2009;104:253-4. https://doi.org/10.1038/ajg.2008.25
  11. Rajwal S, Davison S, Wyatt J, McClean P. Primary Epstein-Barr virus hepatitis complicated by ascites with epstein-barr virus reactivation during primary cytomegalovirus infection. J Pediatr Gastroenterol Nutr 2003; 37:87-90. https://doi.org/10.1097/00005176-200307000-00016
  12. Touge C, Agawa H, Sairenji T, Inoue Y. High incidence of elevated antibody titers to Epstein-Barr virus in patients with uveitis. Arch Virol 2006;151:895-903. https://doi.org/10.1007/s00705-005-0686-7
  13. Kim SY, Ryu IS, Baek SH, Chung KS, Koh H. Concurrent reactivation of latent EBV with hepatitis A can affect clinical feature of childhood hepatitis. Acta Paediatr 2010;99:1258-62. https://doi.org/10.1111/j.1651-2227.2010.01752.x
  14. Obel N, Hoier-Madsen M, Kangro H. Serological and clinical findings in patients with serological evidence of reactivated Epstein-Barr virus infection. APMIS 1996; 104:424-8. https://doi.org/10.1111/j.1699-0463.1996.tb00737.x
  15. Chung JL, Kim HS. Clinical usefulness of EBV-specific antibody panel test and PCR genotyping in the diagnosis of Epstein-Barr virus infection. Korean J Clin Pathol 2000;20:320-9.
  16. Luderer R, Kok M, Niesters HG, Schuurman R, de Weerdt O, Thijsen SF. Real-time Epstein-Barr virus PCR for the diagnosis of primary EBV infections and EBV reactivation. Mol Diagn 2005;9:195-200. https://doi.org/10.1007/BF03260091
  17. Rowe M, Zuo J. Immune responses to Epstein-Barr virus: molecular interactions in the virus evasion of CD8+ T cell immunity. Microbes Infect 2010;12:173-81. https://doi.org/10.1016/j.micinf.2009.12.001
  18. Ternak G. Epstein-Barr virus reactivation. Lancet Infect Dis 2003;3:271. https://doi.org/10.1016/S1473-3099(03)00603-0
  19. Siegl G, Weitz M. Pathogenesis of hepatitis A: persistent viral infection as basis of an acute disease? Microb Pathog 1993;14:1-8. https://doi.org/10.1006/mpat.1993.1001
  20. Vallbracht A, Maier K, Stierhof YD, Wiedmann KH, Flehmig B, Fleischer B. Liver-derived cytotoxic T cells in hepatitis A virus infection. J Infect Dis 1989;160: 209-17. https://doi.org/10.1093/infdis/160.2.209
  21. Rickinson AB, Moss DJ, Allen DJ, Wallace LE, Rowe M, Epstein MA. Reactivation of Epstein-Barr virusspecific cytotoxic T cells by in vitro stimulation with the autologous lymphoblastoid cell line. Int J Cancer 1981; 27:593-601. https://doi.org/10.1002/ijc.2910270505
  22. Fukuda M, Satoh TA, Takanashi M, Hirai K, Ohnishi E, Sairenji T. Inhibition of cell growth and Epstein-Barr virus reactivation by CD40 stimulation in Epstein-Barr virus-transformed B cells. Viral Immunol 2000;13:215-29. https://doi.org/10.1089/vim.2000.13.215
  23. Annels NE, Kalpoe JS, Bredius RG, Claas EC, Kroes AC, Hislop AD, et al. Management of Epstein-Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconstitution. Clin Infect Dis 2006; 42:1743-8. https://doi.org/10.1086/503838
  24. Asada H, Miyagawa S, Sumikawa Y, Yamaguchi Y, Itami S, Suguri S, et al. CD4+ T-lymphocyte-induced Epstein-Barr virus reactivation in a patient with severe hypersensitivity to mosquito bites and Epstein-Barr virus-infected NK cell lymphocytosis. Arch Dermatol 2003;139:1601-7. https://doi.org/10.1001/archderm.139.12.1601